J&J Is Focused on Fighting Cancer, Not Obesity Drugs, CEO Says

Johnson & Johnson's CEO, Joaquin Duato, has clarified that the company is prioritizing its efforts in fighting cancer rather than entering the lucrative obesity drug market. This decision sets J&J apart from competitors who are aggressively pursuing weight-loss medications, following the success of similar drugs from companies like Eli Lilly & Co. and Novo Nordisk. By focusing on cancer, J&J aims to make significant strides in a field with critical health implications, underscoring the company's commitment to areas with the potential for transformative impact on public health.